Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income: 2010-2025

Historic Net Income for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Net Income fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.49% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Net Income stood at -$3.4 million for Q3 2025, which was up 82.30% from -$19.3 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Net Income peaked at -$1.4 million during Q1 2021, and registered a low of -$28.0 million during Q4 2021.
  • For the 3-year period, Lineage Cell Therapeutics' Net Income averaged around -$6.3 million, with its median value being -$5.2 million (2023).
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Net Income was 82.82% (2021), while the steepest drop was 2,946.44% (2021).
  • Lineage Cell Therapeutics' Net Income (Quarterly) stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then rose by 25.90% to -$4.7 million in 2023, then spiked by 31.06% to -$3.2 million in 2024, then fell by 13.96% to -$3.4 million in 2025.
  • Its Net Income stands at -$3.4 million for Q3 2025, versus -$19.3 million for Q2 2025 and -$6.0 million for Q1 2025.